ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 23.8% on Saturday . The company traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.83 ($0.06). 16,731,404 shares were traded during trading, a decline of 23% from the average session volume of 21,725,510 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Performance
The stock has a market capitalization of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53. The company has a 50-day moving average of GBX 2.46 and a 200-day moving average of GBX 1.95.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- The Basics of Support and Resistance
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- How to Profit From Growth Investing
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
